The Asia Pacific region has recently become an area of focus for the conduct of clinical trials. Orphan Reach has expanded its operations into countries like India, China and the wider Pacific Rim.
In addition to the obvious recruitment potential arising from populations in excess of one billion people like India and China, the Asia Pacific region offers a vast array of diseases with many rare diseases very prevalent.
Furthermore, the cost of conducting clinical research in the region can be significantly lower compared to the US and Western Europe. In combination with the cost effective Orphan Reach delivery model clear budgetary advantages can be achieved.
Quality and compliance remain to be fundamental factors and sometimes there can be a perception, similarly to Central and Eastern Europe before it became very popular for the conduct of clinical research, that emerging regions such as Asia Pacific are lagging behind. However, many sites across the region are already fully ICH GCP trained and compliant and Orphan Reach work closely with our operational teams on the ground to evaluate each individual site before including them in our sponsor’s projects.
The local knowledge and direct contact on the ground are critical to the successful conduct of clinical studies in the Asia Pacific region and reinforces why you can count on Orphan Reach to deliver your projects here.